ストックスクリーナーアプリを入手
0.7535
5.81%
-0.0465
アフターアワーズ：
.77
0.0165
+2.19%
前日終値:
$0.80
開ける：
$0.789
24時間の取引高:
734.48K
Relative Volume:
1.01
時価総額：
$127.62M
収益：
$3.25M
当期純損益:
$-116.80M
株価収益率:
-0.247
EPS:
-3.05
ネットキャッシュフロー:
$-98.17M
1週間 パフォーマンス:
-22.06%
1か月 パフォーマンス:
-15.27%
6か月 パフォーマンス:
-73.93%
1年 パフォーマンス:
-83.83%
1日の値動き範囲:
$0.7513
$0.818
1週間の範囲:
$0.7513
$0.9597
52週間の値動き範囲:
$0.7513
$4.83
Rapt Therapeutics Inc Stock (RAPT) Company Profile
名前
Rapt Therapeutics Inc
セクター
電話
(650) 489-9000
住所
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
RAPT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
0.7535 | 127.62M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-26 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | ダウングレード | Stifel | Buy → Hold |
| 2024-11-11 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-11-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-05-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-02-22 | ダウングレード | UBS | Buy → Neutral |
| 2024-02-21 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-02-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | 開始されました | Evercore ISI | Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-09-14 | 開始されました | Berenberg | Buy |
| 2023-08-09 | 開始されました | Stifel | Buy |
| 2023-06-15 | 開始されました | Barclays | Overweight |
| 2023-01-04 | 開始されました | Guggenheim | Buy |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2022-09-21 | 開始されました | CapitalOne | Overweight |
| 2022-05-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-12-09 | 開始されました | JP Morgan | Overweight |
| 2021-08-12 | 開始されました | SVB Leerink | Outperform |
| 2021-06-21 | 開始されました | Piper Sandler | Overweight |
| 2020-06-01 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-04-13 | 開始されました | ROTH Capital | Buy |
| 2019-11-25 | 開始されました | BMO Capital Markets | Outperform |
| 2019-11-25 | 開始されました | UBS | Buy |
| 2019-11-25 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Rapt Therapeutics Inc (RAPT) 最新ニュース
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World
RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks
RAPT Therapeutics Reports First Quarter 2025 Financial Results - The Manila Times
RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView
RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN
RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
JPMorgan Chase & Co. Raises Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News
A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com
Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com
Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX
Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance
RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada
RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa
Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks
RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus
RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire
Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World
Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN
Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World
Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World
RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada
RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks
RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan
Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks
RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks
RAPT Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
RAPT THERAPEUTICS Earnings Results: $RAPT Reports Quarterly Earnings - Nasdaq
RAPT Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
RAPT Therapeutics, Inc. SEC 10-K Report - TradingView
Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c) - TipRanks
Can RAPT's $231M War Chest and New Food Allergy Drug Transform Its Future? - StockTitan
RAPT Therapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
RAPT Therapeutics (RAPT) to Release Quarterly Earnings on Thursday - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts - Defense World
Still Cautious Over RAPT Therapeutics’ Fresh Start With RPT904 (NASDAQ:RAPT) - Seeking Alpha
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
SG Americas Securities LLC Purchases 42,636 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Leerink Partnrs Has Positive Outlook of RAPT FY2024 Earnings - Armenian Reporter
FY2024 Earnings Forecast for RAPT Issued By Leerink Partnrs - Defense World
All You Need to Know About Rapt Therapeutics (RAPT) Rating Upgrade to Buy - Yahoo Finance
RAPT Therapeutics Inc (NASDAQ: RAPT) Up 31.9% From 52-Week Low; YTD Falls -26.58% – Here’s What To Do Now - Marketing Sentinel
Rapt Therapeutics Inc (RAPT) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):